companies innovating obesity treatment glp-1 drugs 2025 💰 US & Europe. Biggest drug race in medical history. 3 frontiers. All accelerating NOW. 🟢 Approximately $100 billion market. Eli Lilly: $1 TRILLION market cap. Oral pill FDA approved How Employers Can Manage GLP-1

These signals included dizziness (ROR, 1.30, 95% CI 1.271.33), tremor (1.37, 1.321.42), dysgeusia (1.72, 1.641.81), lethargy (1.24, 1.151.33), taste disorder (2.55, 2.332.80), presyncope (1.39, 1.251.54), parosmia (2.39, 2.072.75), allodynia (25.55, 21.7130.08), hypoglycemic unconsciousness (8.11, 6.949.46), brain fog (1.78, 1.512.10), hyperesthesia (1.40, 1.181.66), diabetic neuropathy (1.95, 1.612.36), hypoglycemic seizure (3.29, 2.324.66), ophthalmic migraine (3.14, 1.885.27), Wernickes encephalopathy (2.37, 1.394.04), diabetic hyperglycemic coma (3.07, 1.685.62), hyperglycemic unconsciousness (7.94, 4.2714.77), vagus nerve disorder (3.75, 1.927.32), and hyperglycemic seizure (5.85, 1.8118.90) (Fig

The saturation heuristic is best understood as a plausibility argument for why a figure near 100 mcg is not obviously absurd, not as evidence that it is correct

Factors such as your baseline metabolic rate, genetic makeup, underlying insulin resistance, hormonal imbalances, and starting weight all influence how strongly and quickly you respond to GLP-1 medications

Nagel, R